620533-94-0 Usage
Uses
Used in Pharmaceutical Research and Development:
5-Pyrimidinepropanoic acid, β-oxo-, methyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a promising candidate in the development of new drugs, particularly those targeting specific biological pathways or diseases.
Used in Medical Research:
In the field of medical research, 5-Pyrimidinepropanoic acid, β-oxo-, methyl ester serves as a valuable tool for studying the mechanisms of action of certain biological processes. Its potential biological properties make it useful in understanding and potentially treating various medical conditions.
Used in Industrial Production:
5-Pyrimidinepropanoic acid, β-oxo-, methyl ester is used as a key component in the production of specific compounds or materials in various industries. Its unique chemical properties contribute to the development of novel products with specialized applications.
Used in Chemical Synthesis:
As a synthetic compound, 5-Pyrimidinepropanoic acid, β-oxo-, methyl ester is used in chemical synthesis processes to create a range of derivative compounds. These derivatives may have applications in different sectors, including pharmaceuticals, materials science, and other industries.
Check Digit Verification of cas no
The CAS Registry Mumber 620533-94-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,0,5,3 and 3 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 620533-94:
(8*6)+(7*2)+(6*0)+(5*5)+(4*3)+(3*3)+(2*9)+(1*4)=130
130 % 10 = 0
So 620533-94-0 is a valid CAS Registry Number.
620533-94-0Relevant academic research and scientific papers
TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
-
Page/Page column 51, (2010/02/07)
This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C1-C3 alkane-diyl; R1 is phenyl, which is optionally substituted with one to three substitutents indpendently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)
